⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1770651 | 1.00 | — | — | |
| SCHEMBL1770653 | 1.00 | — | — | |
| SCHEMBL25777170 | 0.83 | — | — | |
| SCHEMBL206183 | 0.73 | — | — | |
| SCHEMBL369237 | 0.73 | — | — | |
| SCHEMBL4401196 | 0.72 | — | — | |
| SCHEMBL940931 | 0.72 | — | — | |
| SCHEMBL13754181 | 0.71 | — | — | |
| SCHEMBL14201515 | 0.69 | — | — | |
| SCHEMBL3297300 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4712969-A1 | CYCLIN INHIBITORS | Circle Pharma, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4688789-A1 | MACROCYCLIC RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4665454-A1 | IMIDAZOTRIAZINE IL-17A MODULATORS AND USES THEREOF | Dice Alpha, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12465643-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2025-11-11 | — | — | US | disclosed |
| WO-2025226861-A1 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| US-20250319187-A1 | RAS INHIBITORS | REVOLUTION MEDICINES INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12409225-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2025-09-09 | — | — | US | disclosed |
| US-12403196-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250255964-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-08-14 | — | — | US | disclosed |
| US-20250242029-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT | 2025-07-31 | — | — | US | disclosed |
| EP-1377593-A2 | 2-AMINO-PROPANOL DERIVATIVES | Novartis AG (CH) | 2004-01-07 | — | — | EP | disclosed |
| WO-2003082880-A1 | SILICON DERIVATIVES OF AMINO ACIDS | JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG (DE) | 2003-10-09 | — | — | WO | disclosed |
| WO-2002076995-A2 | 2-AMINO-PROPANOL DERIVATIVES | NOVARTIS AG (CH) | 2002-10-03 | — | — | WO | disclosed |
| US-6416861-B1 | COMBINATORIAL CHEMISTRY | NORTHWESTERN UNIVERSITY | 2002-07-09 | — | — | US | disclosed |
| WO-2002039997-A2 | ACE-2 MODULATING COMPOUNDS AND USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-05-23 | — | — | WO | disclosed |
| WO-2000049022-A2 | ORGANOSILICON COMPOUNDS AND USES THEREOF | NORTHWESTERN UNIVERSITY (US) | 2000-08-24 | — | — | WO | disclosed |
| US-5629293-A | Single chain peptide compounds having hemoregulatory activity | NYCOMED IMAGING AS (NO) | 1997-05-13 | — | — | US | disclosed |
| EP-0643725-A1 | SINGLE CHAIN PEPTIDE COMPOUNDS HAVING HEMOREGULATORY ACTIVITY | NYCOMED IMAGING AS (NO) | 1995-03-22 | — | — | EP | disclosed |
| CN-1085912-A | Peptide compounds | HAFSLUND NYCOMED AS (NO) | 1994-04-27 | — | — | CN | disclosed |
| WO-1993024524-A1 | SINGLE CHAIN PEPTIDE COMPOUNDS HAVING HEMOREGULATORY ACTIVITY | HAFSLUND NYCOMED AS (NO) | 1993-12-09 | — | — | WO | disclosed |